Rare diseases present unique challenges, often beginning with diagnosis. Symptoms may puzzle patients and even leave health care providers uncertain. Diagnostic tests and tools may be difficult to access, buried behind health plan red tape. For patients who do finally find answers, treatment may be out of reach.

These challenges ring true for a rare disease called amyloidosis, caused by a build-up of abnormal protein in different bodily organs. Depending upon how the disease manifests, patients can experience debilitating symptoms like dizziness and nerve tingling, nausea and vomiting, extreme pain, undetectable blood pressure, kidney damage, swollen legs or shortness of breath. As symptoms worsen, patients become less mobile and more dependent on the care of loved ones. Progressive and multifaceted, amyloidosis can levy a tremendous burden on patients and their families.

ABOUT TRANSTHYRETIN AMYLOIDOSIS

There are several types of amyloidosis. This white paper addresses transthyretin amyloidosis, which can be hereditary. The disease’s symptoms may appear unrelated at first. They are often confused for other conditions. They may manifest at different times and can vary depending on which type of amyloidosis a patient has. Because no single, easy diagnostic test exists, patients can go for years without a
diagnosis or even get misdiagnosed. The condition worsens with time, leaving patients to experience effects on their nervous, cardiac, renal and digestive systems, among others.

Yet the outlook for patients with transthyretin amyloidosis is much brighter than that of some other rare disease patients. After years with no treatment options, patients with this type of amyloidosis now have three FDA-approved treatments. They vary in mode of delivery – oral, injection or infusion - and in which presentation of amyloidosis they treat. But all have the potential to significantly improve patients’ lives, if patients are able to access them. Health care system complexities, coverage barriers and high out-of-pocket costs, however, can make accessing treatment difficult.

**THE STRUGGLE FOR DIAGNOSIS AND TREATMENT**

America’s health care system can work well for everyday people with everyday ailments. But health plan policies can present challenges to patient-centered care for rare conditions like amyloidosis. There are access barriers at nearly every turn. Health plans often require patients’ first point of contact to be a primary care doctor. These family clinicians are adept at diagnosing common complications such as ear infections and establishing routine treatment of, for example, high blood pressure. But they may not connect seemingly unrelated amyloidosis symptoms. Patients may need to see a specialist, or several, before they can gain an amyloidosis diagnosis. Insurance may require a referral for each one.

Making matters worse, insurers may also require prior authorization or impose other coverage barriers for necessary diagnostic tests. Finding answers is important, but the many steps and delays in accessing critical testing is difficult for patients and their families.

Once patients have a diagnosis, other insurance barriers can delay
access to treatment for weeks or months. Commercial plans frequently provide better coverage for one amyloidosis medication than for another, requiring additional paperwork or posing onerous barriers for patients who need a different treatment.

Patients covered through Medicare or by the Veterans Health Administration also face challenges. Some depend upon independent patient assistance programs to help cover the high cost of treatment, though navigating these programs can be difficult. Those who can’t secure financial assistance may face out-of-pocket costs that run thousands of dollars each month. These patients’ medication expenses can rival the cost of another mortgage payment—or more—each month. Patients who live near an academic medical center may enroll in a clinical trial to access treatment without the high out-of-pocket costs. Others, however, may simply forego their medication.

**VETERANS HEALTH ADMINISTRATION CHALLENGES**

Patients covered by the Veterans Health Administration may find it challenging to access treatment for amyloidosis. Hereditary transthyretin amyloidosis manifests primarily in one of two ways, through cardiac...
Inconsistent VA coverage sometimes leads clinicians to suggest that patients travel to a different VA location for amyloidosis treatment. But not everyone can travel. And the trend of receiving patients from across the state may burden VA locations that have more favorable coverage policies.”

Marcus Urey, MD
CHALLENGES WITH MEDICARE COVERAGE

Medicare is often more willing than other insurers to approve patients’ use of innovative amyloidosis treatments. Yet Medicare’s siloed structure and cost-sharing policies can keep patients from accessing their approved medication.

Patients covered by Medicare are often required to pay their entire deductible at one time because the monthly out-of-pocket cost for their medicine exceeds that amount. Most commercial plans accept manufacturers’ co-pay coupons, which help patients meet their annual deductible without paying it all out of pocket. Medicare, however, does not permit their use. Medicare’s limits on the use of co-pay coupons is detrimental to patients who don’t have the ability to pay their annual deductible all at once. And the annual deductible is just the first of many out-of-pocket costs for patients.

Medicare Part D’s approach to coinsurance requires patients to pay between 5% and 25% of their medication’s list price, depending on which phase of coverage they are in. This ends up being a few dollars for most generics, but it can be thousands of dollars for a new, rare disease treatment.

In addition to Medicare’s onerous cost sharing requirements, the program is slow to adjust its coverage policies to keep up with recent therapy approvals. For example, Medicare doesn’t cover home infusion of the new amyloidosis medication – even though it covers home infusion for more than 35 other medications. Instead, advanced-stage amyloidosis patients must travel to a hospital or an outpatient center to receive the treatment. This is yet another obstacle that inhibits some patients’ ability to access or continue treatment.

“Patients with coverage through Medicare who are treated where I work have a co-insurance payment of up to $4,000 for a 28-day supply—a cost they must pay entirely out of pocket. Patients with commercial coverage may be required to pay a similar amount, but they can offset their out-of-pocket costs with co-pay coupons and support from patient assistance programs.”

Nitasha Sarswat, MD
CONCLUSION

Transthyretin amyloidosis is one of the few rare diseases that has FDA-approved treatments, yet health systems and policies inhibit patients from a timely diagnosis and access to medications that could slow the progression of their disease.

A significant percentage of amyloidosis patients have health insurance through the Veterans Health Administration or Medicare. Their coverage guidelines and high out-of-pocket costs can impede patients’ ability to access groundbreaking treatments. Such barriers frustrate those living with the condition, their family members and the clinicians who treat them. Policy changes that make financial assistance more accessible could decrease patients’ cost burden.

More treatment options mean more opportunities for clinicians to follow a patient-centered approach, one that allows for tailored treatment for each patient and his or her lifestyle. It’s only possible though, if patients can access the innovative medications that could drastically improve their quality of life.
RARE DISEASES WORKING GROUP MEMBERS

Kelsey Barrell, MD  
Emily Brown, MGC, CGC  
Robert Gottlieb, MD, PhD  
Dinesh Kalra, MD, FACC  
Nitasha Sarswat, MD  
Christina Shen, RN, BSN, MPP  
Francy Shu, MD  
Marcus Anthony Urey, MD

Please note that the views expressed in this document do not necessarily reflect those of the institutions with which working group members are affiliated.

ABOUT THE RARE DISEASES WORKING GROUP

The Rare Diseases Working Group is a network of policy-minded health care providers who advocate for patient-centered care.

To learn more, visit allianceforpatientaccess.org/rare-diseases

*The access issues described in this white paper are long-running challenges that may temporarily be altered or impacted by policy responses to COVID-19.